ClinicalTrials.gg
CompletedNCT01680341BOOST®Updated Apr 2, 2018Results posted

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec/insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 45 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-02.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
44th of 70
272 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
31st of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 44th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 31st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart (IDeg/IAsp) in subjects with type 2 diabetes mellitus previously treated with insulin glargine.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 272 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2 (randomisation)
  • Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase inhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeks prior to Visit 2 (randomisation) and doses should have been stable in this period of time
  • Glycosylated () 7.0-10.0% (both inclusive) by central laboratory analysis
  • (BMI) below or equal to 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones (TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)
  • Stroke; heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)
  • Uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12 months) or hypoglycaemic unawareness as judged by the investigator
  • Life-threatening disease (e.g. cancer)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    IDegAsp Simple

    Drug: insulin degludec/insulin aspart

  • Experimental
    IDegAsp Step wise

    Drug: insulin degludec/insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.

    Also known as: IDegAsp

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.

    Also known as: IDegAsp

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment

    Time frame: Week 0, Week 26

  2. Subjects With HbA1c Below 7.0%

    Number of subjects with HbA1c below 7% after 26 weeks of treatment.

    Time frame: Week 26

  3. Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia

    Percentage of subjects with HbA1c below 7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.

    Time frame: Week 26

  4. Incidence of Treatment Emergent Adverse Events (TEAEs)

    A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: Weeks 0-28

  5. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Weeks 0-27

  6. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period

    Confirmed hypoglycaemic episodes in the maintenance period (from Week 16 to the end of the trial including follow-up \[Week 27\]) consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: From week 16 to end of trial including follow-up (week 27)

  7. Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.

    Time frame: Weeks 0-27

08

Results

Posted Nov 17, 2015

Participant flow

The trial was conducted in 43 sites in 5 countries: Algeria (3 sites), Germany (5 sites), Malaysia (3 sites), Turkey (3 sites), and United States (29 sites).

Participant flow — Overall Study
MilestoneIDegAsp SimpleIDegAsp Step Wise
Started136136
Exposed135134
Completed115119
Not completed2117
Withdrew: Adverse event32
Withdrew: Unclassified1815

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin) (%)

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Least squares mean · Percent (%) glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
Percent (%) glycosylated haemoglobinIDegAsp SimpleIDegAsp Step Wise
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)-1.45 ± 0.09-1.33 ± 0.09
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment

Time frame:
Week 0, Week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegAsp SimpleIDegAsp Step Wise
Change From Baseline in Fasting Plasma Glucose (FPG)-1.68 ± 0.23-1.98 ± 0.23
SecondarySubjects With HbA1c Below 7.0%

Number of subjects with HbA1c below 7% after 26 weeks of treatment.

Time frame:
Week 26
Reported as:
Number · Subjects
Subjects With HbA1c Below 7.0%
SubjectsIDegAsp SimpleIDegAsp Step Wise
Subjects With HbA1c Below 7.0%9185
SecondaryPercentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia

Percentage of subjects with HbA1c below 7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.

Time frame:
Week 26
Reported as:
Number · percentage of subjects
Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia
percentage of subjectsIDegAsp SimpleIDegAsp Step Wise
Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia25.432.0
SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs)

A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
Weeks 0-28
Reported as:
Number · number of events
Incidence of Treatment Emergent Adverse Events (TEAEs)
number of eventsIDegAsp SimpleIDegAsp Step Wise
Incidence of Treatment Emergent Adverse Events (TEAEs)242286
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Weeks 0-27
Reported as:
Number · episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
episodesIDegAsp SimpleIDegAsp Step Wise
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes552323
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period

Confirmed hypoglycaemic episodes in the maintenance period (from Week 16 to the end of the trial including follow-up \[Week 27\]) consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
From week 16 to end of trial including follow-up (week 27)
Reported as:
Number · episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period
episodesIDegAsp SimpleIDegAsp Step Wise
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period230143
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.

Time frame:
Weeks 0-27
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes
episodesIDegAsp SimpleIDegAsp Step Wise
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes8249

Adverse events

Collected over The adverse events were collected from week 0 to Week 28.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp Simple—7/135 (5.2%)45/135 (33.3%)
IDegAsp Step Wise—10/134 (7.5%)53/134 (39.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIDegAsp SimpleIDegAsp Step Wise
HypoglycaemiaMetabolism and nutrition disorders2/1350/134
Acute coronary syndromeCardiac disorders0/1351/134
Aortic valve stenosisCardiac disorders0/1351/134
Coronary artery diseaseCardiac disorders1/1351/134
Coronary artery occlusionCardiac disorders0/1351/134
Ventricular fibrillationCardiac disorders0/1351/134
Abdominal pain lowerGastrointestinal disorders0/1351/134
HaemorrhoidsGastrointestinal disorders0/1351/134
Pancreatitis acuteGastrointestinal disorders0/1351/134
Ischaemic strokeNervous system disorders0/1351/134
Most frequent other events
Most frequent other events
EventIDegAsp SimpleIDegAsp Step Wise
NasopharyngitisInfections and infestations12/13520/134
Upper respiratory tract infectionInfections and infestations14/13510/134
InfluenzaInfections and infestations5/13512/134
HeadacheNervous system disorders9/1358/134
DiarrhoeaGastrointestinal disorders5/1358/134
Back painMusculoskeletal and connective tissue disorders6/1358/134
BronchitisInfections and infestations6/1357/134

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDegAsp SimpleIDegAsp Step WiseTotal
Mean58.8 ± 9.859.1 ± 9.458.9 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp SimpleIDegAsp Step WiseTotal
Female6053113
Male7683159
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegAsp SimpleIDegAsp Step WiseTotal
Mean8.2 ± 0.98.2 ± 0.98.2 ± 0.9
Fasting plasma glucose
Fasting plasma glucose(mmol/L)IDegAsp SimpleIDegAsp Step WiseTotal
Mean7.8 ± 2.38.1 ± 3.08.0 ± 2.6
09

Study locations

45 sites
  • Novo Nordisk Investigational Site
    Goodyear, Arizona 85395, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Spring Valley, California 91978, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Saint Petersburg, Florida 33709, United States
  • Novo Nordisk Investigational Site
    Suwanee, Georgia 30024, United States
  • Novo Nordisk Investigational Site
    Avon, Illinois 46123, United States
  • Novo Nordisk Investigational Site
    Crystal Lake, Illinois 60012, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Waltham, Massachusetts 02453, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29407, United States
  • Novo Nordisk Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75251, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76132, United States
  • Novo Nordisk Investigational Site
    Olympia, Washington 98502, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Kenosha, Wisconsin 53144, United States
  • Novo Nordisk Investigational Site
    Algiers, 16000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Tizi Ouzou, 16015, Algeria
  • Novo Nordisk Investigational Site
    Erdmannhausen, 71729, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    Pohlheim, 35415, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Cheras, 56000, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Selangor, 46150, Malaysia
  • Novo Nordisk Investigational Site
    Antalya, 07050, Turkey
  • Novo Nordisk Investigational Site
    Denizli, 20070, Turkey
  • Novo Nordisk Investigational Site
    Gaziantep, 27070, Turkey
  • Novo Nordisk Investigational Site
    Hatay, 31040, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34752, Turkey
10

References and documents

Publications

  • Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN(R) Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17. PubMed 23710902 ↗
  • Haluzik M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Jul;20(7):1585-1592. doi: 10.1111/dom.13261. Epub 2018 Mar 25. PubMed 29451706 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
  • Gerety G, Bebakar WM, Chaykin L, Ozkaya M, Macura S, Herslov ML, Behnke T. TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS. Endocr Pract. 2016 May;22(5):546-54. doi: 10.4158/EP15893.OR. Epub 2015 Dec 31. PubMed 26720250 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Aug 2013, 11 months.

Results were first posted in Nov 2015, 2 years 2 months after primary completion. A results delay was requested in Nov 2013.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2012
First posted
Sep 7, 2012
StartActual
Aug 31, 2012
Primary completionActual
Aug 22, 2013
CompletionActual
Aug 22, 2013
Results delay requested
Nov 7, 2013
Results first posted
Nov 17, 2015
Last update
Apr 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01680341
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 7, 2012
Start date
Aug 31, 2012
Primary completion
Aug 22, 2013
Completion
Aug 22, 2013
Results posted
Nov 17, 2015
Last update
Apr 2, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion